Predict your next investment

AMO Pharma company logo
HEALTHCARE | Biotechnology
amo-pharma.com

See what CB Insights has to offer

Founded Year

2015

Stage

Series B | Alive

Total Raised

$60M

Last Raised

$35M | 2 yrs ago

About AMO Pharma

AMO Pharma is working to identify and advance promising therapies for the treatment of serious and debilitating diseases in patient populations with significant areas of unmet need, including rare genetic diseases. AMO Pharma is currently advancing two investigational therapies for treatment of fragile X syndrome and myotonic dystrophy, and is in the process of licensing additional development-stage products in diverse areas including autism and other CNS disorders.

AMO Pharma Headquarter Location

152-160 City Road

London, England, EC1V 2NX,

United Kingdom

+44 (0) 1483 319070

Latest AMO Pharma News

AMO Pharma Awarded Innovation Passport For AMO-02 (Tideglusib) For Treatment Of Congenital Myotonic Dystrophy Type 1

Aug 17, 2021

AMO Pharma Awarded Innovation Passport For AMO-02 (Tideglusib) For Treatment Of Congenital Myotonic Dystrophy Type 1 Company's lead clinical candidate receives innovative medicine designation under new program designed to accelerate drug approval process and improve patient access in United Kingdom Author: Aug 17, 2021 3:00 AM EDT LONDON, Aug. 17, 2021 /PRNewswire/ -- AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare, childhood-onset neurogenetic disorders with limited or no treatment options, today announced that the Company has received innovative licensing and access pathway (ILAP) designation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for AMO-02 (tideglusib), an investigational therapy in development for the treatment of congenital myotonic dystrophy type 1 (CDM1). The MHRA launched the ILAP program in January 2021 to support innovative approaches to the safe, timely and efficient development of promising medicines to improve patient access in the UK. The Innovative Passport, a new medicine designation, is the first step in the ILAP process, triggering the MHRA and its partner agencies, including the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and National Health Service (NHS) England, to create a target development profile that outlines a unique product-specific roadmap for regulatory and development milestones with the goal of early patient access in the UK. More information about the ILAP program can be found here: https://www.gov.uk/guidance/innovative-licensing-and-access-pathway . "This Innovation Passport designation is among the first ever granted to a company developing promising therapies for diseases of the central nervous system (CNS) including developmental disorders such as CDM1, showing that the MHRA recognizes the urgent need for a treatment option for these patients," said Joseph Horrigan, MD, chief medical officer at AMO Pharma. "The MHRA's decision is an important step in our efforts to bring a potential treatment to CDM1 patients living in the UK as rapidly as possible and we look forward to continued collaboration with the agency and its partners as we advance our AMO-02 clinical development program." CDM1 is a rare genetic disease that presents itself at birth and is characterized by cognitive and physical impairment. Symptoms can include autism spectrum symptoms including difficulty with thinking and problem solving, weakened muscles and speech, and hearing and vision difficulties. There are currently no approved therapies for CDM1. Patients are typically treated with therapies to address different symptoms of the disease. Many patients also receive support through special education and speech and physical therapy. AMO-02 accesses brain, muscle and other tissues and has been shown to reduce the DMPK expansion repeat mRNA that is the pathological basis for CDM1. In addition to Innovation Passport designation, AMO-02 has received Fast Track and Rare Pediatric Disease Designations by the U.S. Food and Drug Administration (FDA). "Congenital myotonic dystrophy is a devastating disease that significantly affects the quality of life of patients, their families and caregivers. It is encouraging to see the MHRA grant this new designation to AMO-02, targeting the underlying cause of the disease and recognising the urgent need for new therapies for those currently living without any treatments," said Peter Ashley of Cure DM UK Charity. "This is an important milestone for patients and families in the UK, giving hope that a new treatment might soon be available to our DM community around the world." AMO-02 is currently being assessed in an ongoing pivotal trial, called the REACH-CDM study, that is being conducted at 11 treatment centers globally and plans to enroll a total of 56 patients who will be assessed on a range of measures of CNS features and muscle function associated with CDM1. For more information on REACH-CDM, visit https://www.reachcdm.com . About AMO-02 AMO-02 (tideglusib) is in development for the treatment of congenital myotonic dystrophy and has potential for use in additional CNS, neuromuscular and other orphan indications. AM0-02 is a clinical stage investigational medicine for the treatment of the severe form of congenital myotonic dystrophy known as CDM1 or Steinert disease. AMO-02 has a dual mechanism disrupting the pathogenic RNA repeat in CDM1 and inhibiting excess levels of the kinase GSK3β. About AMO Pharma AMO Pharma is a biopharmaceutical company working to identify and advance promising therapies for the treatment of serious and debilitating diseases in patient populations with significant areas of unmet need, including rare and severe childhood onset neurogenetic disorders with limited or no treatment options. In addition to developing AMO-02 for congenital myotonic dystrophy, the company is also progressing AMO-01 as a clinical stage treatment for Phelan-McDermid syndrome and AMO-04 as a clinic-ready potential medicine for Rett syndrome and related disorders. AMO-02, AMO-01 and AMO-04 are investigational medicines that have not yet been approved for the treatment of patients anywhere in the world. For more information, please visit the AMO Pharma website at http://www.amo-pharma.com/ . Media: View original content: https://www.prnewswire.com/news-releases/amo-pharma-awarded-innovation-passport-for-amo-02-tideglusib-for-treatment-of-congenital-myotonic-dystrophy-type-1-301355195.html

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing AMO Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

AMO Pharma is included in 3 Expert Collections, including Rare Diseases.

R

Rare Diseases

229 items

B

Biopharmaceuticals

13,989 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

N

Neuroscience

2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

AMO Pharma Patents

AMO Pharma has filed 1 patent.

The 3 most popular patent topics include:

  • Autosomal recessive disorders
  • Neurological disorders
  • Psychiatric diagnosis
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/25/2018

Syndromes, Rare diseases, Autosomal recessive disorders, Psychiatric diagnosis, Neurological disorders

Application

Application Date

10/25/2018

Grant Date

Title

Related Topics

Syndromes, Rare diseases, Autosomal recessive disorders, Psychiatric diagnosis, Neurological disorders

Status

Application

AMO Pharma Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

AMO Pharma Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.